Critical Review of Commercial Influences,  Ethical Concerns, and Impact on Rational  Healthcare

Dr Anand  Shankar

doi:10.51168/sjhrafrica.v6i12.2355

Authors

Dr Anand Shankar Prof of General Medicine Department of General Medicine Netaji Subhash Medical College and Hospital, Bihta, Patna, Bihar.

DOI:

https://doi.org/10.51168/sjhrafrica.v6i12.2355

Keywords:

Academic enterprise, commercial theater, commercial influences

Abstract

Medical conferences in India have evolved from small academic gatherings to large-scale events attracting thousands of participants. While ostensibly serving as platforms for continuing medical education (CME) and knowledge dissemination, these conferences increasingly reflect the commercial interests of pharmaceutical companies and other healthcare industry stakeholders. This critical review examines the current landscape of medical conferences in India, analyzing the extent of pharmaceutical industry involvement, associated ethical concerns, regulatory frameworks, financial implications, and the impact on rational prescribing and healthcare delivery. Through examination of existing literature, regulatory guidelines, and documented cases from the Indian context, this article argues that many medical conferences have transformed into marketing platforms that prioritize commercial interests over genuine academic advancement, raising serious questions about medical professionalism and patient welfare.

References

Anant, T.C.A., et al. (2018). "Pharmaceutical industry and medical practice in India: A case of regulatory failure." Economic and Political Weekly, 53(15), 45-52.

Association of Physicians of India. (2019). "Code of Medical Ethics." API Guidelines Publication.

Basu, S., & Garg, S. (2020). "Conflict of interest in medical practice and education in India: Time for transparency." National Medical Journal of India, 33(1), 1-3.

Chatterjee, P. (2019). "India bans 328 fixed-dose combination drugs." The Lancet, 393(10180), 1511.

Das, S., & Choudhury, S. (2019). "Pharmaceutical marketing practices in India: Are patients being harmed?" Indian Journal of Medical Ethics, 4(4), 277-282.

Department of Pharmaceuticals, Government of India. (2024). "Uniform Code for Pharmaceutical Marketing Practices (UCPMP) - Revised Guidelines."

Gagnon, M.A., & Lexchin, J. (2018). "The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States." PLoS Medicine, 5(1), e1.

Gokhale, K. (2015). "Dose of Reality: Inside India's Loophole-Ridden Generic Drugs Boom." The Print, investigative series.

Indian Medical Association. (2021). "Code of Ethics for Medical Practitioners." IMA Publication.

Jain, N., et al. (2021). "Conflicts of interest in medical education: Pharmaceutical sponsorship of Indian conferences." Journal of Postgraduate Medicine, 67(2), 98-103.

Kamat, V.R., & Gaikwad, N. (2019). "Assessment of rationality of fixed dose combinations approved in India." Indian Journal of Pharmacology, 51(1), 29-33.

Kumar, R., & Singh, A. (2020). "Pharmaceutical industry's influence on medical practice in India: Implications for rational prescribing." Indian Journal of Community Medicine, 45(4), 412-416.

Lo, B., & Field, M.J. (Eds.). (2009). "Conflict of Interest in Medical Research, Education, and Practice." National Academies Press, Washington DC.

Medical Council of India. (2002). "Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002."

Mukherjee, D., & Saha, A. (2018). "Industry-sponsored continuing medical education and prescribing patterns: An Indian perspective." Journal of Clinical and Diagnostic Research, 12(5), IC01-IC04.

National Medical Commission. (2023). "Professional Conduct Regulations - Amendment 2023."

Oldani, M.J. (2014). "Deep pharma: Psychiatry, anthropology, and pharmaceutical detox." Culture, Medicine, and Psychiatry, 38(2), 255-278.

Organisation of Pharmaceutical Producers of India (OPPI). (2022). "OPPI Code of Pharmaceutical Marketing Practices."

Prasad, V., & Mailankody, S. (2017). "Research and development spending to bring a single cancer drug to market and revenues after approval." JAMA Internal Medicine, 177(11), 1569-1575.

Press Council of India. (2017). "Report on Pharmaceutical Industry Practices and Medical Profession."

Rao, K.D., & Bhatnagar, A. (2020). "The Medical Council of India's regulations on physicians' interactions with pharmaceutical and allied healthcare industries: A critical appraisal." Indian Journal of Medical Ethics, 5(1), 5-9.

Roy, V., & Rewari, B.B. (2019). "Ambiguous position on transparency: The case of payments to doctors in India." British Medical Journal, 367, l5723.

Sarpatwari, A., et al. (2019). "Marketing of medical devices before and after regulatory authorization, 1976-2015." JAMA Internal Medicine, 179(10), 1369-1376.

Shetty, P. (2015). "India's pharmaceutical industry takes off." The Lancet, 385(9974), 1238-1239.

Srivastava, D., et al. (2018). "Are medical conferences worth it? An analysis of the educational value and commercial influences." Journal of Evidence-Based Medicine, 11(2), 106-112.

Steinbrook, R., et al. (2017). "Justification and disclosure of pharmaceutical industry payments to physicians in medical journal publications." JAMA, 317(17), 1724-1725.

Thawani, V. (2017). "Rational prescribing and continuing medical education in India: Need for reform." Indian Journal of Pharmacology, 49(1), 1-3.

The Print Investigation Team. (2015). "The Money Trail: How pharmaceutical companies influence Indian doctors." The Print investigative series.

World Health Organization. (2010). "Ethical Criteria for Medicinal Drug Promotion." WHO Publications.

Yadav, P., & Sharma, M. (2021). "Conference culture and conflicts of interest: A survey of Indian physicians." Indian Journal of Medical Ethics, 6(2), 112-118.